Mitral valve prolapse (MVP) is a disorder characterized by changes in the structure and function of the mitral valve, located between the left atrium and left ventricle of the heart. In MVP, the valve leaflets bulge into the atrium during systole, which can lead to regurgitation, i.e. backflow of blood from the ventricle to the atrium. This condition can be asymptomatic or cause a variety of clinical manifestations, from no symptoms to pain, fatigue, and abnormal heart rhythms. In this text, we review the main aspects of mitral valve prolapse, including the history, epidemiology, genetic predisposition, risk factors, diagnosis, treatment, and monitoring.
History of the disease and interesting historical facts
Mitral valve prolapse was first described by the medical community in the mid-20th century, but the first mentions of problems with the functioning of the mitral valve can be found in even earlier records. In 1966, Dr. Martin Bivas, after studying 300 patients with heart disease, identified mitral valve prolapse as a significant component necessary for further understanding of the pathology. Research in the 1980s showed that MVP is more common than previously thought, and its observation became an important area for cardiologists. In modern cardiology guidelines, MVP is considered a syndrome that can be either independent or associated with other connective tissue diseases.
Epidemiology
Mitral valve prolapse is a common cardiovascular disease, which, according to various sources, occurs in 2-3% of the population. In most cases, MVP occurs in women, and the ratio of women to men is approximately 3:1. Analysis of epidemiological data shows that among young people (under 30 years old), MVP is detected more often, while in older people, the additional risk is associated with other cardiac pathologies. According to statistics, in 10-15% cases, MVP can lead to clinical manifestations, which requires diagnosis and observation.
Genetic predisposition to this disease
There is a multiple genetic predisposition to developing mitral valve prolapse. Research shows that certain mutations in genes responsible for the synthesis of collagen and other components of connective tissues can increase the likelihood of developing this disease. In particular, the COL1A1 and COL3A1 genes, which are responsible for the structure of collagen, are key in these processes. In some cases, MVP manifests itself as a hereditary condition, especially if there are close relatives with a similar diagnosis. Family analysis shows that the presence of MVP in one family member is associated with an increased likelihood of its occurrence in others.
Risk factors for the development of this disease
The main risk factors for the development of mitral valve prolapse include both physical and chemical parameters of the environment, as well as the patient's personal characteristics. Among them are:
- Heredity: the presence of mitral valve prolapse or other connective tissue diseases in relatives.
- Age: The disease is more common in young and older patients.
- Gender: MVP is diagnosed significantly more often in women than in men.
- Connective tissue conditions: diseases such as Marfan syndrome or Ehlers-Danlos syndrome.
- Emotional stress: High stress can aggravate the valve condition.
- Other cardiovascular diseases: Having underlying heart disease may increase your risk.
Diagnosis of this disease
Diagnosis of mitral valve prolapse begins with an assessment of clinical symptoms. The main symptoms include:
- Chest pain that may radiate to the left arm.
- Shortness of breath, especially during physical exertion.
- Heartbeat or rhythm, changes in the cardiac cycle.
- Fatigue and general weakness.
Laboratory tests may include a complete blood count, blood chemistry, and electrolyte balance. Radiological tests such as echocardiography can help visualize the valve apparatus and determine the degree of prolapse. Holter and exercise monitoring may also be used to assess cardiac activity over time.
It is also important to perform a differential diagnosis to exclude other diseases that have similar symptoms, such as coronary heart disease or other cardiomyopathies.
Treatment
Treatment of mitral valve prolapse depends on the severity of clinical manifestations and may range from observation to surgical intervention.
General treatment includes lifestyle interventions and risk factor management, such as blood pressure control, physical activity, and exercise regimen.
Pharmacological treatment is aimed at relieving symptoms. Beta-blockers are used to control heart rhythm and reduce symptoms. In severe cases, antiarrhythmic therapy may be prescribed.
Surgical treatment is indicated when regurgitation is severe enough to cause significant symptoms or threat to the patient. The most common surgical procedures involve repair or replacement of the mitral valve.
Other treatments, including biofeedback and physical therapy, may be helpful in helping a patient recover from surgery.
List of medications used to treat this disease
There are several groups of drugs that may be effective for mitral valve prolapse:
- Beta-blockers (eg, metoprolol).
- Antiarrhythmic drugs (eg, flecainide).
- Anticoagulants (if there is thrombus formation).
- Drugs that improve blood circulation (eg, Trental).
Disease monitoring
Monitoring of mitral valve prolapse involves regular εξε measurements by a cardiologist, which allows tracking the dynamics of the valve condition and clinical manifestations. Control stages include echocardiographic studies, which allow determining changes in valve function and the presence of regurgitation. The prognosis is favorable in most cases. However, some patients may experience complications, including pulsar arrhythmias, infective endocarditis, or aortic diseases.
Age-related features of the disease
Mitral valve prolapse has its own characteristics in different age groups. In young people, the disease is often asymptomatic or has minimal symptoms. In older patients, more pronounced symptoms are observed, such as shortness of breath and heart failure, which is associated with age-related changes in the cardiovascular system.
Questions and Answers
- Is mitral valve prolapse dangerous? In most cases, the disease is asymptomatic and does not pose a danger, but can lead to complications in severe forms.
- How is mitral valve prolapse diagnosed? Diagnosis is made using physical examination, echocardiography and additional radiological studies.
- What are the main symptoms of the disease? The main symptoms include shortness of breath, chest pain, palpitations and fatigue.
- What treatments are used for mitral valve prolapse? Treatment may include observation, drug therapy, and surgery depending on the severity of the disease.
- How often should you undergo examination for mitral valve prolapse? An annual examination by a cardiologist is recommended, especially if symptoms or complications are present.
